[Expression changes and clinical significance of annexin V in maternal blood and placenta in patients with preeclampsia]
- PMID: 21426764
[Expression changes and clinical significance of annexin V in maternal blood and placenta in patients with preeclampsia]
Abstract
Objective: To evaluate the expression of annexin V in maternal blood and placenta, and to explore the relationship between annexin V and preeclampsia (PE).
Methods: 120 women with PE who delivered babies in the Second Hospital of Hebei Medical University from December 2007 to December 2009 were chosen as study groups. They were classified into four groups: early-onset mild group (n = 30), early-onset severe group (n = 30), late-onset mild group (n = 30) and late-onset severe group (n = 30). 30 women without perinatal complications who accepted elective term cesarean section were chosen as control group. Western blot and immunohistochemistry were used to detect the expression and localization of annexin V in placenta and maternal blood. Flow cytometry was employed to detect the apoptosis of cytotrophoblast. AnnexinVmRNA level was determined by reverse transcription (RT)PCR. Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FiB), international normalized ratio (INR) were detected in each group.
Results: (1) The expression of annexin V in placenta and maternal blood were: 0.54 ± 0.12 and 0.62 ± 0.17 in early-onset mild group; 0.47 ± 0.15 and 0.56 ± 0.24 in early-onset severe group; 0.74 ± 0.23 and 1.08 ± 0.32 in late-onset mild group; 0.68 ± 0.28 and 0.72 ± 0.21 in late-onset severe group; 1.73 ± 0.35 and 1.55 ± 0.27 in control group. They were significantly lower in PE groups than in control group (P < 0.05). However, there was no significant difference among PE groups (P > 0.05). (2) The early apoptosis, late apoptosis percentage of trophoblast cells were: 3.21%, 0.86%, in early-onset mild group; 5.32%, 0.72%, in early-onset severe group; 2.43%, 0.63%, in late-onset mild group; 4.28%, 0.48% in late-onset severe group; 1.05%, 0.59%, in control group. Early apoptosis percentage in each group of PE was higher than that in control group (P < 0.05). However, there was no significant difference among PE groups (P > 0.05). (3) The annexin V mRNA levels in placenta were: 25.0 ± 3.0 in early-onset mild group; 24.8 ± 3.0 in early-onset severe group; 25.4 ± 3.9 in late-onset mild group; 25.1 ± 2.7 in late-onset severe group, respectively. All were significantly higher than that in control group (30.6 ± 3.0, P < 0.05), and no significant difference was found among PE groups (P > 0.05). (4) PT, APTT, FiB, INR levels were: (11.3 ± 2.4), (25.6 ± 2.9) s, (4.6 ± 0.9) g/L and 0.9 ± 0.2 in early-onset mild group; (12.1 ± 1.9), (27.2 ± 2.1) s, (5.0 ± 1.0) g/L and 0.9 ± 0.2 in early-onset severe group; (11.7 ± 2.3), (26.5 ± 2.3) s, (5.0 ± 0.7) g/L and 0.8 ± 0.3 in late-onset mild group; (11.4 ± 2.6), (27.3 ± 3.0) s, (4.3 ± 0.8) g/L and 0.8 ± 0.3 in late-onset severe group; (12.4 ± 2.7), (28.0 ± 1.9) s, (5.1 ± 1.2) g/L and 0.9 ± 0.2 in control group. There was no significant difference among PE groups and control group (P > 0.05).
Conclusion: The expression changes of annexin V in placenta and maternal blood were observed in patients with PE. This indicated that annexin Vplayed an important role in the pathogenesis and progression of PE by affecting coagulation.
Similar articles
-
[Expression changes of the growth arrest and DNA damage 45 alpha gene in placenta in patients with preeclampsia and its clinical significance].Zhonghua Fu Chan Ke Za Zhi. 2010 Nov;45(11):833-7. Zhonghua Fu Chan Ke Za Zhi. 2010. PMID: 21211282 Chinese.
-
[Expression of vitronectin in placental basal plate and its relationship with the pathogenesis of severe preeclampsia].Zhonghua Fu Chan Ke Za Zhi. 2013 Mar;48(3):171-6. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 23849937 Chinese.
-
[Relationship between the expression of human leukocyte antigen G and preeclampsia].Zhonghua Fu Chan Ke Za Zhi. 2011 Oct;46(10):758-62. Zhonghua Fu Chan Ke Za Zhi. 2011. PMID: 22321350 Chinese.
-
Wnt/β-catenin signaling pathway in trophoblasts and abnormal activation in preeclampsia (Review).Mol Med Rep. 2017 Aug;16(2):1007-1013. doi: 10.3892/mmr.2017.6718. Epub 2017 Jun 7. Mol Med Rep. 2017. PMID: 29067442 Review.
-
Pre-eclampsia: pathophysiology and clinical implications.BMJ. 2019 Jul 15;366:l2381. doi: 10.1136/bmj.l2381. BMJ. 2019. PMID: 31307997 Review.
Cited by
-
Targeting Neutrophil Extracellular Trap Formation: Exploring Promising Pharmacological Strategies for the Treatment of Preeclampsia.Pharmaceuticals (Basel). 2024 May 9;17(5):605. doi: 10.3390/ph17050605. Pharmaceuticals (Basel). 2024. PMID: 38794175 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical